Ann: Appendix 4E and Annual Report, page-29

Cash Outflow to June 2024 $101m Including almost doubling directors remuneration whilst share price has reduced from 31 cents to six cents since 2020.
Cash on hand June 2024 $93m . Less than one years cash left.

Capital raise coming or we are sold.

Capital Raising likely as so far IMU have been hopeless at taking cash from shareholder and creating wealth.
We have zero therapies sold or made it to market. I can say this as I am here since 2017.
I have made money along the way trading but thats trading. I still expect the asset to increase in value. Thats the directors job. Create wealth for shareholders.
We should not lose sight of the scorecard of financial performance.

Leslie and Pauls salaries have gone up exponentially whilst not delivering any value to shareholders.
With only 20% financial KPIS and 80% non financial, the measuring stick for rewarding directors is not towards creating wealth for shareholders and in my view it should be 80% KPI for shareholder wealth creation. Not 20%
Its fair to ask ' Where is the fruit' from our investment
I am here till I see data on the 4 trials and assess my position from there.
I felt the need to rant after seeing the embarrassing salaries provided to directors who I am yet to see create value for patients or shareholders. This statement is made from 8 years experience as a shareholder.
We have no therapies approved for use and no shareholder value created